enVVeno Medical Corporation (NVNO)
enVVeno Medical Corporation operates in the Medical - Devices industry of the Healthcare sector, headquartered in Irvine, CA, US. The stock last traded at $11.00, down 1.17% on the session, giving a market capitalisation of $181,533. On trailing twelve-month figures it carries a trailing P/E of -0.02, a net margin of 0.0%. Its beta of 1.09 implies it has historically moved more than the broad market.
enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.
enVVeno Medical Corporation is most often compared with the following Healthcare names: